Disease onset in familial and sporadic primary progressive multiple sclerosis

• Published in: Multiple sclerosis 2010-06, Vol.16 (6), p.694-700
• Main Authors: Koch, M., Zhao, Y., Yee, I., Guimond, C., Kingwell, E., Rieckmann, P., Sadovnick, D., Tremlett, H.
• Format: Article
• Language: English
• Subjects: Age of Onset; Biological and medical sciences; Databases, Factual; Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases; Disease Progression; Female; Humans; Longitudinal Studies; Male; Medical sciences; Multiple sclerosis and variants. Guillain barré syndrome and other inflammatory polyneuropathies. Leukoencephalitis; Multiple Sclerosis, Chronic Progressive - epidemiology; Multiple Sclerosis, Chronic Progressive - genetics; Neurology; Risk Factors; Sex Factors; Statistics, Nonparametric
• ISSN: 1352-4585; 1477-0970
• DOI: 10.1177/1352458510367661

The pathophysiology of primary progressive (PP) multiple sclerosis (MS) involves diffuse axonal degeneration which is believed to start early in the disease process, even before the onset of clinical symptoms. Symptomatic onset then occurs when this process reaches a threshold after which the axonal loss can no longer be compensated. A preliminary study showed that patients with familial PPMS had an earlier clinical onset than patients with sporadic disease, suggesting a hereditary component to the disease process of PPMS. In this study, we combined data from two large, population-based, longitudinal MS databases to investigate disease onset in familial and sporadic PPMS. We examined 411 patients with PPMS. There were no differences in gender distribution or onset symptoms between familial and sporadic PPMS. Patients with familial PPMS were significantly younger at disease onset (n = 84, median age: 37.6 years) than patients with sporadic disease (n = 327, median age: 42.7, p = 0.007). This difference was due to a greater proportion of familial cases with a disease onset before the age of 30 and a smaller proportion with disease onset between 40 and 50 years of age (p = 0.002). Gender had no significant effect on the age at disease onset. Further analyses showed that these findings were unlikely to be due to ascertainment bias towards an earlier diagnosis in familial cases. Our findings suggest a hereditary component to the disease process of PPMS. It would be worthwhile to identify patients with familial PPMS for future research on disease modifying genes in MS.